Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...